AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00693446
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive Tacrolimus from day 0 to the end of the study. The time of first administration will be within the first 48 hours post transplant.~The dose of tacrolimus will be administrated twice a day. The initial dose will be 0,1 mg/day po. then titrated to maintain trough whole-blood concentrations between 5-15 ng/ml.~Patients receive also rATG , mycophenolate mofetil and corticosteroids.
Trial: NCT04185077
Drug: Bivalirudin
RxNorm normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bivalirudin (Salubris Pharmaceuticals Co) was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion, a reduced-dose infusion (0.2mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of0.3mg/kgwasgivenif the activatedclotting time 5minutes after the initial bolus (measuredwith the Hemotec assay) was less than 225 seconds.
Trial: NCT00395499
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02783547
Drug: SyB C-1101 and Azacytidine
DrugBank: Cytidine (DB02097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study is a multi-center open-label study to assess the tolerability of oral administration of SyB C-1101 twice daily from Day 1 to Day 21 in combination with subcutaneous administration or intravenous drip infusion of azacitidine once daily at a dose of 75 mg/m2 (body surface) for 7 days during the period between Day 8 and Day 16, and to estimate the recommended dose (RD) of C-1101.~SyB C-1101 will be administered at a daily dose of 560 mg or 840 mg in each of the 2 cohorts for a treatment period of 1 cycle for 28 days, including 21 days for SyB C-1101 treatment followed by 7 days of follow-up.
Trial: NCT02044224
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine 0.4 µg/kg/hr infusion (from the start of anaesthesia until the end of anaesthesia).~Anaesthesia induction: propofol 2 mg/kg, rocuronium 0.6 mg/kg iv, and fentanyl 2-3 mikrogram/kg.~Anaesthesia maintenance: sevoflurane and oxygen 50%, rocuronium 0.1-0.2 mg/kg iv, fentanyl 1 mikrogram/kg as required
Trial: NCT00076089
Drug: Roflumilast
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00095472
Drug: L-NMMA
RxNorm normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00095472
Drug: Sodium Nitrite
RxNorm normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04090957
Drug: Estetrol oral tablet
RxNorm normalized name: drospirenone / estetrol Oral Tablet
DrugBank: Estetrol (DB12235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Estetrol oral tablet will be administered orally once daily.
Trial: NCT03172754
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PD-1 inhibitor
Trial: NCT03172754
Drug: Axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tyrosine kinase inhibitor
Trial: NCT03930771
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 150 to 200 mg/m2 orally on days 10 through 14.
Trial: NCT00589706
Drug: MAb-425
RxNorm normalized name: B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB
DrugBank: Elranatamab (DB15395)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAb425 anti-epidermal growth receptor) and Iodine-125 will be given as an injection for a total of three treatments each separated by one week.
Trial: NCT01491061
Drug: Ranolazine
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: os, 1,000 mg twice 12 hours apart prior to PCI
Trial: NCT00008411
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Every 3 weeks at a starting dose of 75 mg/m2 IV over 1 hour on day 1, repeated every 21 days.
Trial: NCT00008411
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 35 mg/m2 IV over 30 minutes on days 1, 8, and 15, for 3 weeks followed by one week of rest repeated every 28 days.
Trial: NCT03572231
Drug: mirabegron
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03572231
Drug: darifenacin
RxNorm normalized name: Darifenacin
DrugBank: Darifenacin (DB00496)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral
Trial: NCT03572231
Drug: imidafenacin
RxNorm normalized name: imidafenacin
DrugBank: Imidafenacin (DB09262)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: oral
Trial: NCT03572231
Drug: tolterodine
RxNorm normalized name: Tolterodine
DrugBank: Tolterodine (DB01036)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03572231
Drug: oxybutynin
RxNorm normalized name: Oxybutynin
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03572231
Drug: trospium
RxNorm normalized name: Trospium
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03572231
Drug: fesoterodine
RxNorm normalized name: Fesoterodine
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01415583
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.5mg/kg (max dose 20mg)
Trial: NCT03276728
Drug: AMG 986 IV
RxNorm normalized name: AMG-222
DrugBank: AMG-222 (DB06011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 986 solution for infusion
Trial: NCT03276728
Drug: AMG 986 PO
RxNorm normalized name: AMG-222
DrugBank: AMG-222 (DB06011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 986 tablets for oral (PO) administration
Trial: NCT00236288
Drug: Bupropion and intensive behavioral therapy
RxNorm normalized name: bupropion and dextromethorphan
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To prescribe bupropion and behavioral therapy to patients and/or their families, who are currently receiving radiation.
Trial: NCT01032187
Drug: Meglumine antimoniate
RxNorm normalized name: meglumine antimoniate
DrugBank: Meglumine antimoniate (DB13732)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg/kg/day IV for 20 days
Trial: NCT01032187
Drug: Amphotericin B-deoxycholate
RxNorm normalized name: deoxycholate
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B-deoxycholate 1 mg/kg/day IV for 14 days
Trial: NCT03302689
Drug: Levobupivacaine Solution
RxNorm normalized name: levobupivacaine Injectable Solution
DrugBank: Levobupivacaine (DB01002)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TAP-block with Levobupivacaine 0,3% - 25 ml from each side
Trial: NCT03302689
Drug: Ropivacaine Solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TAP-block with Ropivacaine 0,3% - 25 ml from each side
Trial: NCT00023933
Drug: iodine I 131 monoclonal antibody CC49-deltaCH2
RxNorm normalized name: iodine I-131
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03611881
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 or 8 weeks of nicotine patch given in a tapering dose of 21 mg, 14 mg, 7 mg.
Trial: NCT01506635
Drug: Timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04447235
Drug: Ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use of the combination of ivermectin plus losartan as early treatment for COVID-19 in cancer patients
Trial: NCT04447235
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use of the combination of ivermectin plus losartan as early treatment for COVID-19 in cancer patients
Trial: NCT00292071
Drug: caspofungin acetate
RxNorm normalized name: Caspofungin Acetate
DrugBank: Caspofungin (DB00520)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (50 mg/m²/day and 70 mg/m²/day) Caspofungin will be given for a minimum of 4 days (or at least 2 separate days of 7-point plasma sampling). Patients will be administered caspofungin for a maximum of 28 days.
Trial: NCT04019288
Drug: Batiraxcept
RxNorm normalized name: Batiraxcept
DrugBank: Batiraxcept (DB17522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03805932
Drug: Moxetumomab Pasudotox-tdfk
RxNorm normalized name: moxetumomab pasudotox-tdfk
DrugBank: Moxetumomab pasudotox (DB12688)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Moxetumomab pasudotox-tdfk is administered at 30-40 ug/Kg intravenous (iv) over 30 min given on days 1, 3, 5 of each cycle.
Trial: NCT03254628
Drug: oxytocin and misoprostol
RxNorm normalized name: naproxen and misoprostol
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This study did not provide uterotonic drugs except in the case of stock out where locally purchased oxytocin and misoprostol were provided only as back up.
Trial: NCT02079909
Drug: T-817MA-L
RxNorm normalized name: (T,G)-A-L
DrugBank: Glatiramer (DB05259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 224 mg T-817 MA once daily
Trial: NCT00720356
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10mg/kg administered intravenously every 2 weeks
Trial: NCT00720356
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg/daily orally
Trial: NCT02429804
Drug: Fludeoxyglucose F-18
RxNorm normalized name: Fludeoxyglucose F-18
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02429804
Drug: Fluorine F 18 Sodium Fluoride
RxNorm normalized name: Fluorine F-18
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01295138
Drug: Lactulose
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lactulose liquid. 15mls twice daily
Trial: NCT02183493
Drug: BI 1356
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03805932
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 12 mg Cycle 1, Day -2; Cycles 2-8, Day 1. Administer 0.5-2 hours before rituximab/Ruxience. If participant has previous reaction to rituximab/Ruxience, give 12mg. If participants tolerate rituximab/Ruxience without problems, may hold at discretion of provider. Pre-medications are given prior to rituximab/Ruxience on day 1.
Trial: NCT03805932
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25-50 mg Cycle 1, Day -2; Cycles 2-8, Day 1. Pre-medications are given prior to rituximab/Ruxience on day 1. May be given prior to moxetumomab pasudotox-tdfk at discretion of principal investigator.
Trial: NCT04498650
Drug: PQ912
RxNorm normalized name: Pralsetinib
DrugBank: Pralsetinib (DB15822)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: PQ912 50 mg tablets and 150 mg tablets
Trial: NCT01374321
Drug: TRO40303
RxNorm normalized name: TRO40303
DrugBank: TRO40303 (DB16031)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg, peripheral IV, single dose just before balloon inflation, slow bolus (35ml/min)
Trial: NCT03805932
Drug: Famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20-40 mg Cycle 1, Day -2; Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and is recommended every 12 hours x 2 after the end of infusion; Cycles 2-8, Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and is recommended every 12 hours x 2 after the end of infusion. Pre-medications are given prior to rituximab/Ruxience on day 1.
Trial: NCT03805932
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 81 mg Cycle 1, Days 1-8; Cycles 2-8, Days 1-8. Only if platelet counts ≥ 100 x 109/L.
Trial: NCT00025571
Drug: HPPH
RxNorm normalized name: HPPH
DrugBank: 2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a (DB15243)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04262466
Drug: Brenetafusp
RxNorm normalized name: Brenetafusp
DrugBank: Brenetafusp (DB19441)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brenetafusp IV infusions
Trial: NCT04262466
Drug: Brenetafusp and pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brenetafusp and pembrolizumab IV infusions
Trial: NCT04262466
Drug: Brenetafusp and chemotherapy
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Brenetafusp (DB19441)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brenetafusp and chemotherapy IV infusions
Trial: NCT04262466
Drug: Brenetafusp and monoclonal antibodies and chemotherapy
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Brenetafusp (DB19441)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brenetafusp and a monoclonal antibody therapy and chemotherapy
Trial: NCT04262466
Drug: Brenetafusp and tebentafusp
RxNorm normalized name: Tebentafusp
DrugBank: Tebentafusp (DB15283)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Brenetafusp and tebentafusp IV infusions
Trial: NCT04262466
Drug: Brenetafusp and bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brenetafusp and bevacizumab IV infusions
Trial: NCT04262466
Drug: Brenetafusp and kinase inhibitors
RxNorm normalized name: VEGFR 2 Kinase inhibitor I
DrugBank: Brenetafusp (DB19441)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brenetafusp and oral kinase inhibitors
Trial: NCT03955783
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by mouth
Trial: NCT03955783
Drug: Selinexor
RxNorm normalized name: Selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given by mouth
Trial: NCT03427814
Drug: Pamiparib
RxNorm normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg orally twice daily
Trial: NCT00115973
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03890770
Drug: BMS-986165
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral administration
Trial: NCT00245388
Drug: Muraglitazar
RxNorm normalized name: Muraglitazar
DrugBank: Muraglitazar (DB06510)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00598923
Drug: topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg twice per day for 3 months
Trial: NCT00598923
Drug: topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 twice per day for 6 days after loading dose of phenytoin
Trial: NCT03621072
Drug: Fluconazole 150mg Capsule Originator
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150mg fluconazole capsule (originator) manufactured at Pfizer Fareva, Amboise, France
Trial: NCT03621072
Drug: Fluconazole 150mg Capsule Localized Originator
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150mg Fluconazole capsule (localized originator) manufactured at Pfizer, Dalian, China
Trial: NCT03377595
Drug: Exparel
RxNorm normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TAP (Transversus Abdominis Plane) block
Trial: NCT03377595
Drug: Exparel
RxNorm normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Wound infiltration
Trial: NCT00046332
Drug: GW810781
RxNorm normalized name: GW810781
DrugBank: GW810781 (DB16032)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04020133
Drug: Plain bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15ml of plain bupivacaine 0.5% will be given in both blocks
Trial: NCT01955707
Drug: natalizumab
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered as described in the treatment arm
Trial: NCT01234038
Drug: ISIS EIF4E Rx
RxNorm normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle
Trial: NCT01234038
Drug: ISIS EIF4E Rx
RxNorm normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle
Trial: NCT01234038
Drug: ISIS EIF4E Rx
RxNorm normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8, and 15 of each 21 day cycle
Trial: NCT01234038
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg/m2 administered as a 3-hour intravenous infusion on Day 1 of each 21 day cycle
Trial: NCT01234038
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC 6.0 mg/mL/min administered as a 1-hour intravenous infusion on Day 1 of each 21 day cycle
Trial: NCT02014259
Drug: semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg
Trial: NCT02259725
Drug: regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT00332579
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily
Trial: NCT02396108
Drug: Paclitaxel + Carboplatin + ASLAN001
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Phase I~* IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle~* IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle~* PO ASLAN001 daily continuously (starting dose 500mg BID)~Phase II~•PO ASLAN 001 daily continuously at the recommended phase II dose x 2 weeks~Followed by:~* IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle x 4 cycles~* IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle x 4 cycles~* PO ASLAN001 daily continuously at the recommended phase II dose x 12 weeks
Trial: NCT02469701
Drug: nivolumab and ablation
RxNorm normalized name: nivolumab and relatlimab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00620373
Drug: Technetium (99mTc) sestamibi
RxNorm normalized name: technetium (99mTc) sestamibi
DrugBank: Technetium Tc-99m sestamibi (DB09161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.
Trial: NCT04401150
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-ml solution of either normal saline (0.9% NaCl) or dextrose 5% in water (D5W) during 30 to 60 minutes, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).
Trial: NCT04401150
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextrose 5% in water of normal saline (0.9% NaCL) in a volume to match vitamin C.
Trial: NCT03962907
Drug: Chlorhexidine, Lifo-Scrub sol 4%®, 500ml, B. Braun
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 - day decolonization procedure prior elective surgery. In carriers with Chlorhexidine daily showers and Mupirocin twice a day nasal ointment. In non-carriers Chlorhexidine showers will be used.
Trial: NCT02225704
Drug: Radium-223 and enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04069949
Drug: sorafenib; toripalimab
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stage I: cohort A: sorafenib 400 mg qd+ toripalimab 240 mg d1; q3w cohort B: sorafenib 400 mg bid, toripalimab 240 mg d1; q3w Stage II: According to the expansion dose based on stage I, subjects are enlarged to 39.
Trial: NCT00212875
Drug: epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00293813
Drug: Alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate 70 mg PO QW